Insurance benefits for the new leukemia drug Xospata have been applied, but clinics are expressing regret. Acute Myeloid Leukemia (AML) treatment Xospata has been reimbursed since March.

Looking at the benefit criteria of this drug, remission-induction therapy is recognized in patients with FLT3 mutant acute myeloid leukemia who are refractory to conventional treatment or can transplant homologous hematopoietic stem cells. Considering the preparation period for the transplantation of homologous hematopoietic stem cells, additional administration of 2 cycles is required only if the transplantation of homologous hematopoietic stem cells is approved in advance. Xospata's administration is limited to up to